HC Wainwright Issues Pessimistic Estimate for PTGX Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Stock analysts at HC Wainwright dropped their Q4 2025 EPS estimates for shares of Protagonist Therapeutics in a note issued to investors on Monday, November 11th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $0.87 for the quarter, down from their prior estimate of $0.88. HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $2.33 per share. HC Wainwright also issued estimates for Protagonist Therapeutics' FY2028 earnings at $2.81 EPS.

PTGX has been the topic of a number of other research reports. JPMorgan Chase & Co. increased their price objective on Protagonist Therapeutics from $39.00 to $48.00 and gave the company an "overweight" rating in a report on Thursday, July 25th. Wedbush reissued an "outperform" rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research report on Monday, November 4th. Truist Financial assumed coverage on shares of Protagonist Therapeutics in a report on Monday, September 9th. They set a "buy" rating and a $60.00 price objective for the company. BTIG Research lifted their target price on shares of Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a "buy" rating in a report on Wednesday, July 24th. Finally, JMP Securities cut their target price on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a "market outperform" rating for the company in a research report on Wednesday, August 7th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Protagonist Therapeutics has a consensus rating of "Buy" and an average price target of $53.57.

Protagonist Therapeutics Trading Down 1.2 %

NASDAQ PTGX traded down $0.50 during trading on Wednesday, hitting $42.67. 594,301 shares of the company traded hands, compared to its average volume of 733,652. Protagonist Therapeutics has a 12 month low of $15.58 and a 12 month high of $48.89. The business has a fifty day simple moving average of $45.64 and a 200 day simple moving average of $38.46. The company has a market capitalization of $2.54 billion, a P/E ratio of 16.00 and a beta of 2.17.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. boosted its stake in Protagonist Therapeutics by 405,061.2% in the 3rd quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company's stock valued at $78,034,000 after buying an additional 1,733,662 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Protagonist Therapeutics by 2,135.6% during the second quarter. Millennium Management LLC now owns 958,283 shares of the company's stock valued at $33,205,000 after acquiring an additional 915,418 shares during the period. Perceptive Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,268,735 shares of the company's stock valued at $43,962,000 after purchasing an additional 274,412 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Protagonist Therapeutics by 813.4% in the 2nd quarter. Renaissance Technologies LLC now owns 297,467 shares of the company's stock worth $10,307,000 after purchasing an additional 264,900 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Protagonist Therapeutics during the 2nd quarter worth about $5,467,000. Institutional investors and hedge funds own 98.63% of the company's stock.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 14,203 shares of the firm's stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total value of $631,891.47. Following the sale, the chief financial officer now directly owns 34,960 shares in the company, valued at $1,555,370.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director William D. Waddill sold 8,000 shares of the company's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the transaction, the director now directly owns 12,000 shares in the company, valued at approximately $540,000. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Asif Ali sold 14,203 shares of the firm's stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total value of $631,891.47. Following the completion of the transaction, the chief financial officer now directly owns 34,960 shares of the company's stock, valued at approximately $1,555,370.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.40% of the company's stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.